Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial

BACKGROUND: Elobixibat is an oral treatment candidate for chronic constipation with a novel mechanism of action via inhibition of the ileal bile acid transporter. We performed this randomized, double-blind, placebo-controlled, dose-finding phase IIb study in Japanese patients with chronic constipati...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakajima, Atsushi, Seki, Mitsunori, Taniguchi, Shinya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2017
Materias:
Original Article—Alimentary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866829/
https://www.ncbi.nlm.nih.gov/pubmed/28840422
http://dx.doi.org/10.1007/s00535-017-1383-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866829/
https://www.ncbi.nlm.nih.gov/pubmed/28840422
http://dx.doi.org/10.1007/s00535-017-1383-5

Ejemplares similares